According to the draft amendment to the Drug Management Law, companies that produce or sell pharmaceuticals without a permit, or that produce or sell fake drugs, will face fines up to 30 times the value of the products involved. Existing law provides for fines of up to five times the value.
Producing or selling fake drugs will result in the suspension of business and revoked certificates, while the production or sale of substandard drugs will result in fines of up to 15 times the value of the products produced or sold, and may result in other penalties such as business suspension or revoked permits. Current law calls for maximum fines in such cases of three times the value of the products involved.
In addition to fines, perpetrators may also face criminal sentences. Officials in charge of drug supervision will also face heavier punishments in case of violations involving drugs, the amendment said.
In addition, drug producers must immediately recall drugs from the market if they have quality or safety risks, and information about the recall should be shared with the public and drug authorities.
AFD China Newsletter is intended to provide our clients and business partners information only. The information provided on the newsletter should not be considered as professional advice, and should not form the basis of any business decisions.